ArticleFrontiers in oncology2026
Retrospective study of hospitalized breast cancer patients in a Zhuhai-based hospital: analysis spanning over 20 years.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer represents a significant global health burden with distinct epidemiological characteristics in China. This study analyzes the management evolution of breast cancer at a regional medical center in Southern China. Methods: A retrospective analysis was conducted of 5,052 breast cancer patients hospitalized from 2004 to 2024. Data encompassed demographics, clinical characteristics, treatment patterns, costs, and outcomes. Results: The cohort was predominantly female (99.5%) with a mean age of 50.5 years. Most cases (61.3%) were early-stage (Stage I), and 70.3% were covered by rural resident basic medical insurance. A 406% surge in hospitalizations occurred in 2022, while median length of stay significantly decreased from 16.9 to 4.8 days (p < 0.001). Treatment trends showed substantial increases in breast-conserving surgery (21.7% in 2024) and neoadjuvant chemotherapy. Total costs peaked in 2019 (¥31,201) then decreased by 58.9%, with out-of-pocket expenses declining from 49.2% to 37.4%. Logistic regression identified adjuvant chemotherapy as a strong positive predictor of cure (OR = 5.87, 95% CI: 3.14-10.99, p < 0.001). Conclusion: Findings confirm established patterns in age and tumor distribution while revealing regional variations in pathological profiles and surgical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.